Parkinson’s drug comes to market with help of renowned University of Kansas pharmaceutical chemist
A new drug therapy for Parkinson’s disease holds promise to improve life for the estimated 1 million Americans living with the progressive neurological condition. The drug therapy, dubbed Vyalev, is marketed by North Chicago, Illinois-based pharmaceutical firm AbbVie. But one of its inventors is University of Kansas pharmaceutical chemist Valentino Stella, who can claim a long track record of developing drugs that improve people’s lives.
